LOUISVILLE, Ky., Dec. 8 Last week, at the Society forNeuroscience Conference in Washington DC, Neuronetrix announced preliminaryresults from a clinical study of their COGNISION(TM) System to diagnoseAlzheimer's disease. The study was performed with Alzheimer's patients at theUniversity of Kentucky's Sanders-Brown Center for Aging.
The COGNISION(TM) System uses event-related potentials (ERP) to recordbrain activity while the patient listens to a sequence of sounds. Subjectswith Alzheimer's process auditory information differently than healthyindividuals and that difference can be detected with the test.
The ability of the ERP method to diagnose Alzheimer's disease has beendemonstrated in scientific studies at several research laboratories around theworld. In a scientific paper published in 2007, Neuronetrix collaboratorsDrs. Robi Polikar, et al, reported that their ERP classification accuracy"exceeded that of the trained community clinic physicians, and closelyapproached the gold standard performance of the university hospital-basedclinic evaluation."
This phase of the study was primarily performed to evaluate theCOGNISION(TM) System in a real-world clinical setting to test ease of use,patient tolerance, and most importantly, data quality.
"Clinical usability and technical performance were major milestones in ourstudy at the Sanders-Brown Center." "The system exceeded our expectations interms of data quality and we demonstrated the test could be efficientlyperformed on real Alzheimer's patients." K.C. Fadem, Neuronetrix, Inc.
The next clinical study phase for Neuronetrix will be to test theCOGNISION(TM) System in a multi-center trial on patients who have beendiagnosed with Alzheimer's disease using a rigorous diagnostic protocol. Thisprotocol will be similar to that used in the Alzheimer's Disease NeuroimagingInitiative (ADNI), a large international study sponsored by the US NationalInstitutes of Health (NIH).
The ADNI protocol uses psychometric testing, magnetic resonance imaging(MRI), and cerebrospinal fluid analysis (CSF) to accurately characterizeseveral aspects of Alzheimer's disease. Neuronetrix will use these same teststo correlate with the COGNISION(TM) ERP results.
"We want to compare our COGNISION(TM) System with the most advanceddiagnostic methods possible to clearly demonstrate the system's capabilities."Dr. John Barker, Chairman, Neuronetrix, Inc.
Neuronetrix is currently working with several NIH Center's of Excellencein the US and a center in Europe to organize the study which is expected tobegin in the first quarter of 2009.
About Alzheimer's Disease
Alzheimer's disease is a chronic neurodegenerative disease of the brainwhich eventually leads to death. Today, Alzheimer's disease affects over 5million Americans with 500,000 new cases reported each year. The Center forDisease Control recently reported that Alzheimer's disease is the 7th leadingcause of death in the US. Those affected by Alzheimer's disease survive onlyabout half as long as those unaffected and of similar age. In 2005,Medicare/Medicaid spending totaled $112 billion on beneficiaries withAlzheimer's and other dementias.
For information: http://www.neuronetrix.com .
SOURCE Neuronetrix, Inc.